Freedom of Information Request ID
7548
Date of response
September 2022
Q1. In the last three months, how many patients have been treated by your haemophilia centre with the following products?
- Advate
- Adynovi
- Elocta
- Esperoct
- Factor Eight Inhibitor Bypass Activity (FEIBA)
- Hemlibra (standalone)
- Hemlibra in combination with any Factor VIII
- NovoEight
- NovoSeven RT
- Obizur
- Refacto AF
*Please see below
Q2. In the last three months, how many patients were treated with the following products for severe Haemophila A ONLY?
- Advate
- Adynovi
- Elocta
- Esperoct
- Factor Eight Inhibitor Bypass Activity (FEIBA)
- Hemlibra (standalone)
- Hemlibra in combination with any Factor VIII
- NovoEight
- NovoSeven RT
- Obizur
- Refacto AF
*Please see below
*Medway NHS Foundation Trust is not a registered Haemophilia Centre. All local patients are registered with the Regional Haemophilia Centre at Kent and Canterbury Hospital who are contactable via their website.
Shared care is provided and a joint clinic is held at Medway every 3 months in which well/asymptomatic patients with ‘mild’ bleeding disorders are reviewed by the Haemophilia Consultant.
All patients with moderate or severe bleeding disorders are seen only at Canterbury.
Occasionally, a Haemophilia patient may present to the Emergency Department with bleeding, or require treatment prior to elective surgery which is being performed at Medway.
Patients are treated with Factor VIII or IX concentrate as advised by the Haemophilia Centre team, and the Factor Concentrate Product is transferred from Canterbury.
In our Medway Transfusion Laboratory we keep a very limited supply of Advate, Benefix and Novoseven for emergency use only.
FOI Requests
The Freedom of Information Act 2000 provides people with a right of access to a wide range of information held by public authorities, including the NHS.
FOI Disclosure Log
A collection of the most common FOI requests we have received and responded to.